All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Engenious vectors,HSC gene therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: 5AM Ventures
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 11, 2021
Details:
Company’s Engenious™ vectors Delivered without Stem Cell Collection or Myeloablative Conditioning in Outpatient and Low-Resource Settings, Enabling Access Worldwide.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Elamipretide
Therapeutic Area: Rare Diseases and Disorders Product Name: MTP-131
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $4.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 10, 2021
Details:
The Company intends to use the net proceeds from this offering to fund the continued clinical development of elamipretide and for working capital and general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Daratumumab,Hyaluronidase-fihj,Bortezomib
Therapeutic Area: Rare Diseases and Disorders Product Name: Darzalex Faspro
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
Accelerated approval of DARZALEX FASPRO-based combination regimen supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Elamipretide
Therapeutic Area: Rare Diseases and Disorders Product Name: MTP-131
Highest Development Status: Phase II/ Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2021
Details:
DCN suggested that, based on the short half-life of elamipretide, a short-term withdrawal period could be sufficient to measure durable effect on functional or structural cardiac endpoints by demonstrating that improvement is not dependent on continuous exposure to the drug.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: $1,150.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2020
Details:
The collaboration will combine Adrestia’s world leading, synthetic viability platform with GSK’s deep scientific expertise in human genetics, functional genomics, screening, and bioinformatics.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): INO-3107
Therapeutic Area: Rare Diseases and Disorders Product Name: INO-3107
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
The open-label, multicenter INO-3107 Phase 1/2 trial will evaluate the efficacy, safety, tolerability, and immunogenicity of INO-3107 in subjects who have required at least two surgical interventions per year for the past three years for the removal of associated papilloma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tesofensine,Metoprolol Tartrate
Therapeutic Area: Rare Diseases and Disorders Product Name: Tesomet
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
Tesomet was well-tolerated in hypothalamic obesity patients throughout the duration of the 48-week trial, with no clinically meaningful differences in heart rate or blood pressure observed. All patients who entered the OLE study completed it.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Exosome-based therapeutics
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Evox Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 17, 2020
Details:
The collaboration will run over three years and will capitalise on the world-class exosome research environment in Oxford, leveraging exosome therapeutics expertise and resources from both Evox and the University to drive innovation within rare disease drug development.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
